Articles Tagged ‘castration-resistant’

07
Jan
2010

Peter Nelson, M.D., Member, FHCRC

20
Apr
2009

Mendiratta P, Mostaghel E, Guinney J, Tewari AK, Porrello A, Barry WT, NelsonĀ  PS, Febbo PG. Genomic strategy for targeting therapy in castration-resistant prostate cancer. J Clin Oncol. 2009 Apr 20;27(12):2022-9. Epub 2009 Mar 16. PubMed PMID: 19289629. PURPOSE: Despite treatments which lower circulating androgens, advanced prostate cancers often

06
Feb
2009

Harris WP, Mostaghel EA, Nelson PS, Montgomery B; Medscape. Androgen deprivation therapy: progress in understanding mechanisms of resistance and optimizing androgen depletion. Nat Clin Pract Urol. 2009 Feb;6(2):76-85. PubMed PMID: 19198621. Androgen deprivation therapy remains a critical component of treatment for men with advanced prostate cancer, and data support

01
Jun
2008

Montgomery RB, Mostaghel EA, Vessella R, Hess DL, Kalhorn TF, Higano CS, True LD, Nelson PS. Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth. Cancer Res. 2008 Jun 1;68(11):4447-54. PubMed PMID: 18519708. Therapy for advanced prostate cancer centers on suppressing systemic androgens and

22
Apr
2008

Mostaghel EA, Nelson PS. Intracrine androgen metabolism in prostate cancer progression: mechanisms of castration resistance and therapeutic implications. Best Pract Res Clin Endocrinol Metab. 2008 Apr;22(2):243-58. Review. PubMed PMID:18471783. Residual tissue androgens are consistently detected within the prostate tumors of castrate individuals and are thought to play a critical role in